Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.pardrugs.com | |
Market Cap | 173.43 Cr. | |
Enterprise Value(EV) | 175.64 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 8.38 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 16.82 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 26.51 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 55.07 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 2.56 | Calculated using Price: 140.95 |
Dividend Yield | 0.89 | Period Ending 2022-03 |
No. of Shares Subscribed | 1.23 Cr. | 12,304,636 Shares |
FaceValue | 10 | |
Company Profile | ||
PDCL is engaged in the development and manufacture of Active Pharma Ingredients (APIs) for the domestic market as well as for exports to international markets. It currently produce various range of Antacid Molecules which are available in the market and are in great demand. |
1 Day |
|
+0.57% |
1 Week |
|
-2.40% |
1 Month |
|
-5.98% |
3 Month |
|
-2.26% |
6 Month |
|
-11.52% |
1 Year |
|
-14.48% |
2 Year |
|
+175.69% |
5 Year |
|
|
10 Year |
|
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 7.21 | 8.18 | 3.69 | 14.75 | 10.63 | 11.35 | 13.68 | 25.02 | 16.44 | |
Return on Capital Employed (%) | 10.18 | 9.92 | 9.36 | 12.34 | 11.19 | 12.41 | 15.56 | 28.68 | 21.85 | |
Return on Assets (%) | 1.27 | 1.48 | 0.72 | 3.24 | 2.77 | 4.78 | 8.56 | 17.01 | 11.88 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 16 | 17 | 17 | 19 | 21 | 29 | 41 | 52 | 60 | 66 | |
Non Curr. Liab. | 27 | 23 | 19 | 17 | 16 | 10 | 9 | 8 | 4 | 4 | |
Curr. Liab. | 18 | 19 | 22 | 20 | 17 | 12 | 11 | 16 | 15 | 15 | |
Minority Int. | |||||||||||
Equity & Liab. | 61 | 59 | 58 | 56 | 54 | 51 | 60 | 76 | 79 | 85 | |
Non Curr. Assets | 48 | 46 | 43 | 42 | 40 | 37 | 36 | 35 | 35 | 36 | |
Curr. Assets | 14 | 13 | 15 | 14 | 14 | 14 | 24 | 41 | 44 | 49 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 61 | 59 | 58 | 56 | 54 | 51 | 60 | 76 | 79 | 85 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 27 | 33 | 33 | 49 | 42 | 46 | 56 | 61 | 75 | 93 | |
Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Total Income | 27 | 33 | 33 | 49 | 42 | 46 | 56 | 61 | 75 | 94 | |
Total Expenditure | -20 | -26 | -26 | -40 | -34 | -38 | -46 | -45 | -59 | -76 | |
PBIDT | 7 | 8 | 7 | 9 | 8 | 8 | 10 | 16 | 16 | 18 | |
Interest | -4 | -4 | -4 | -3 | -2 | -2 | -1 | -1 | 0 | 0 | |
Depreciation | -2 | -2 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | |
Taxation | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -3 | -3 | -4 | |
Exceptional Items | 2 | ||||||||||
PAT | 1 | 1 | 0 | 2 | 2 | 3 | 5 | 12 | 9 | 10 | |
Adjusted EPS | 1 | 2 | 1 | 3 | 3 | 3 | 4 | 9 | 7 | 8 |
Particulars | 6 years | 2016-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 7 | 5 | 3 | 8 | 12 | 8 | |
Cash Fr. Inv. | 0 | -1 | 0 | -1 | 0 | -3 | |
Cash Fr. Finan. | -5 | -4 | -3 | 1 | 2 | -10 | |
Net Change | 1 | 0 | 0 | 7 | 14 | -5 | |
Cash & Cash Eqvt | 1 | 0 | 0 | 7 | 21 | 16 |
Thu, 16 Mar 2023
Analysts/Institutional Investor Meet/Con. Call Updates
|
|
Wed, 15 Mar 2023
Analysts/Institutional Investor Meet/Con. Call Updates
|
|
Tue, 21 Feb 2023
Investor Presentation
|
Tue, 21 Mar 2023 |
|
|
|
|
|